REPLIGEN CORP acquired BioLife Solutions, Inc. for Total enterprise value of approximately $1.5 billion; $31.00 per BioLife share, a transaction announced in July 2026, structured as Cash-and-stock merger: consideration comprised of 64% Repligen common stock and 36% cash, valuing BioLife at $31.00 per share / ~$1.5B enterprise value. Unanimously approved by both boards; subject to customary closing conditions..
Expands Repligen into the high-growth cell therapy market by adding BioLife's market-leading, high-margin biopreservation media franchise (CryoStor) and cell-processing consumables with attractive recurring revenue; expected to be accretive to top-line growth, adjusted margins and adjusted EPS (>=5c yr1, >=25c yr2) with >=$20M yr-1 synergies.
Expands Repligen into the high-growth cell therapy market by adding BioLife's market-leading, high-margin biopreservation media franchise (CryoStor) and cell-processing consumables with attractive recurring revenue; expected to be accretive to top-line growth, adjusted margins and adjusted EPS (>=5c yr1, >=25c yr2) with >=$20M yr-1 synergies.
The acquisition of BioLife represents a natural next step in the evolution of our strategy and further strengthens our position as a leading provider of mission-critical technologies for biologics manufacturing. BioLife brings a highly differentiated portfolio of products including a market-leading biopreservation media platform and other cell processing tools. This opportunity will expand Repligen's presence in the rapidly growing cell therapy market, broaden our solutions offering to cell therapy customers, and add a deeply embedded, high-margin consumables business with attractive recurring revenue. Just as important, we believe our shared culture of innovation and customer centricity will create a strong foundation for future growth and value creation.Olivier Loeillot, President and CEO of Repligen
Advisory firms were not disclosed for this transaction.